| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Assets of disposal group held-for-sale | 83,170,009 | |||
| Prepaid expenses | 144,159 | |||
| Cash and cash equivalents | 4,474 | |||
| Total current assets | 83,318,642 | |||
| Restricted cash | 7,005 | |||
| Goodwill | 1,684,182 | |||
| Deposits | 49,122 | |||
| Total other assets | 1,740,309 | |||
| Total assets | 85,058,951 | |||
| Liabilities held-for-sale | 23,546,478 | |||
| Other current liabilities | 105,918 | |||
| Operating lease liabilities - current | 135,609 | |||
| Line of credit | 700,000 | |||
| Accrued dividend payable | 1,474,009 | |||
| Accrued expenses | 415,444 | |||
| Accounts payable | 3,298,447 | |||
| Total current liabilities | 29,675,905 | |||
| Total liabilities | 29,675,905 | |||
| Accumulated deficit | -204,645,898 | |||
| Preferred stock-Series FPreferred Stock | 0 | |||
| Preferred stock-Series EPreferred Stock | 0 | |||
| Preferred stock-Series DPreferred Stock | 0 | |||
| Preferred stock-Series CPreferred Stock | 0 | |||
| Preferred stock-Series BPreferred Stock | 0 | |||
| Common stock - par value 0.0001 per share 100,000,000 shares authorized 4,765,729 and 4,754,038 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | 477 | |||
| Additional paid-in capital | 198,347,367 | |||
| Total stockholders' equity (deficit) | -6,298,054 | |||
| Total mezzanine equity-Series GPreferred Stock | 61,681,100 | |||
| Total liabilities, mezzanine equity and stockholders' equity (deficit) | 85,058,951 | |||
Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. (ENTO)